Clinical Trial Update: UKK-0018 as an Immunotherapeutic for Treatment of Peanut Allergies [Phase 1, Phase 2]

View source ↗

Summary

A phase 1/2 trial update indicates Ukko's UKK-0018 immunotherapy for peanut allergy and peanut-induced anaphylaxis is currently recruiting. The sponsor is Ukko …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Peanut Allergy
• Peanut-induced Anaphylaxis

Drugs mentioned

• UKK-0018

Snippet

Sponsor: Ukko Inc | Conditions: Peanut-Induced Anaphylaxis, Peanut Allergy | Phase 1, Phase 2 | Status: RECRUITING